Sort
4,870 grants matching “glp 1”
Clinical Development of JS-K for the Treatment of Cancer
$999,423Joseph Felix Nowoslawski · Jsk Therapeutics, Inc. · R44 · FY2018 · CA
Development of a PO-administered beta-lactam-tarocin combination agent to treat methicillin susceptible and methicillin resistant Staphylococci
$999,396Terry Roemer · Prokaryotics, Inc. · R44 · FY2022 · AI
Therapeutic factor XI blockade for sepsis
$999,329Erik Ian Tucker · Aronora, Inc. · R44 · FY2015 · HL
Development of a novel therapeutic for the treatment of diabetic nephropathy and renal fibrosis
$999,274Fabio Cohen Tucci · Epigen Biosciences, Inc. · R44 · FY2019 · DK
Therapeutic Protein C Activator for Myocardial Ischemia
$999,263Erik Ian Tucker · Aronora, Inc. · R44 · FY2018 · HL
Humanized monoclonal antibodies to treat mucormycosis
$999,218Gary Lazar · Vitalex Biosciences, Llc · R44 · FY2025 · AI
Clinical Development of JS-K for the Treatment of Cancer
$999,183Joseph Felix Nowoslawski · Jsk Therapeutics, Inc. · R44 · FY2017 · CA
Development of a CCKBR-targeting scFv as Therapy for Chronic Pain Patients
$999,105Karin N Westlund-High · University Of New Mexico Health Scis Ctr · UG3 · FY2021 · NS
Preclinical development of teixobactin, a new antibiotic
$999,040Dallas Hughes · Novobiotic Pharmaceuticals, Llc · R44 · FY2018 · AI
In vivo dose finding for IN-002 in neonatal lambs for inhaled immunotherapy of RSV
$999,032Richard A Cone · Mucommune, Llc · R44 · FY2020 · AI
Therapeutic Antibody for CMV
$999,000Lawrence Michael Kauvar · Trellis Bioscience, Inc. · SB1 · FY2017 · AI
HLS- Factor XII Inhibitor for Surface Initiated Thrombosis
$998,771Erik Ian Tucker · Aronora, Inc. · R44 · FY2017 · HL
Therapeutic Protein C Activator for Myocardial Ischemia
$998,750Erik Ian Tucker · Aronora, Inc. · R44 · FY2019 · HL
Phase IIB Transmural Systems Transcatheter Cavopulmonary Bypass Endograft
$998,716Nasser Rafiee · Transmural Systems, Llc · R44 · FY2021 · HL
Pre-Clinical Development of a Intranasal Bivalent gD2/gB2 HSV-2 Mucosal Vaccine
$998,684Ali I. Fattom · Bluewillow Biologics, Inc. · R44 · FY2020 · AI
A Novel Probiotic for the Treatment of Sjogren's Syndrome
$998,658Gary Fanger · Rise Therapeutics, Llc · SB1 · FY2021 · DE
Cyclic Orynotides for Systemic MDR Candidiasis
$998,632Dat Quang Tran · Oryn Therapeutics, Llc · R44 · FY2020 · AI
Interstitial Chemophototherapy with Light-Activated Nanoparticulate Doxorubicin
$998,596Gal Shafirstein · Pop Biotechnologies, Inc · R42 · FY2023 · CA
Development of MRS-2541, a methionyl-tRNA synthetase inhibitor, for Gram positive bacterial infections.
$998,521Elke Lipka · Tsrl, Inc. · R44 · FY2023 · AI
Validation of a Novel Fungicidal Approach for Cryptococcal Meningitis
$998,500Aaron Richard McCabe · Minnetronix, Inc. · R42 · FY2018 · AI
HCMV Therapeutic Antibody Safety Trial
$998,144Lawrence Michael Kauvar · Trellis Bioscience, Inc. · U44 · FY2024 · AI
HCMV Therapeutic Antibody Safety Trial
$998,144Lawrence Michael Kauvar · Trellis Bioscience, Inc. · U44 · FY2023 · AI
Therapeutic Protein C Activator for Myocardial Ischemia
$998,107Erik Ian Tucker · Aronora, Inc. · R44 · FY2017 · HL
Development of MRS-2541, a methionyl-tRNA synthetase inhibitor, for Gram positive bacterial infections.
$997,670Elke Lipka · Tsrl, Inc. · R44 · FY2024 · AI
Development of TP-317 in Ulcerative Colitis
$997,635John Parkinson · Thetis Pharmaceuticals, Llc · R44 · FY2023 · DK